tbuckley/cabot-search huggingface dataset:
PTH-145 Comparison Of Percutaneous Endoscopic Gastrostomy, Megestrol Acetate And Nasogastric Feeding In Patients With Cystic Fibrosis
Authors: S Shabbir, M Zaidi, L Mughal, RJ Bright-Thomas, RB Jones
Journal: Gut (2014)

<h3>Introduction</h3> Malnutrition remains an important and common problem in cystic fibrosis (CF) patients and weight loss associated with poor lung function is considered a predictor of mortality, although weight loss has also been found to be an independent predictor of mortality <sup>1,2</sup>. Our aim was to compare changes in weight and FEV1 in CF patients receiving one of 3 interventions to prevent weight loss at 6 and 12 months: i) Percutaneous Endoscopic Gastrostomy (PEG), ii) oral steroid therapy (megestrol acetate- MA) or iii) nasogastric (NG) tube feeding. <h3>Methods</h3> We retrospectively collected data from hospital record of patients attending the Manchester Adult Cystic Fibrosis Centre (MACFC) between June 1998 and June 2012 including all living patients on any of the interventions. <h3>Results</h3> 53 patients fulfilled criteria at 6 months: 18 MA, 14 NG and 21 PEG. There were significant increases in weight from post-intervention time 0 for MA (mean 3.0 kg, 95% CI: 1.16, 4.85) and NG (mean 2.9 kg, 95% CI: 0.84, 4.97), but not for PEG (mean 1.0 kg, 95% CI: ‑0.64, 2.73). There were no significant changes in FEV1 from time 0 for any of the 3interventions at 6 months; although the ratio of change in FEV1 (6 months:time 0) showed small reductions for all 3 interventions; MA (ratio 0.987, 95% CI: 0.882, 1.104), NG (ratio 0.996, 95% CI: 0.876, 1.133) and PEG (ratio 0.925, 95% CI: 0.836, 1.024). 50 patients fulfilled criteria at 12 months: 16 MA, 13 NG and 21 PEG. There were significant increases in weight from time 0 for MA(mean 2.6 kg, 95% CI: 0.38, 4.78), NG (mean 3.2 kg, 95% CI: 0.73, 5.67) and PEG (mean 2.5 kg, 95% CI: 0.60, 4.46). There were no significant changes in FEV1 over 12 months for any of the 3 interventions although the ratio of change in FEV1 (12 months:time 0) showed small changes for MA (ratio 1.030, 95% CI: 0.923, 1.150), NG (ratio 0.957, 95% CI: 0.840, 1.092) and PEG (ratio 1.041, 95% CI: 0.944, 1.147). <h3>Conclusion</h3> All 3 interventions appear to be equally effective means of improving nutritional status as measured by weight gain, and possibly stabilise lung function. Our study is the first which to compare these 3 different interventions but is limited by the small sample size and lack of a control group. Robust prospective studies comparing interventions to improve nutritional status in these patients are required. <h3>References</h3> Van Biervliet S, De Waele K, Van Winckel M, Robberecht E. Percutaneous endoscopic gastrostomy in cystic fibrosis: patient acceptance and effect of overnight tube feeding on nutritional status. <i>Acta Gastroenterol Belg</i> 2004 Jul-Sep;67(3):241–4 Sharma R, Florea VG, Bolger AP, Doehner W, <i>et al</i>. Wasting as an independent predictor of mortality in patients with cystic fibrosis. <i>Thorax</i> 2001:56:746–750 <h3>Disclosure of Interest</h3> None Declared.
Endoscopic treatment using a knife to correct complete anastomotic obstruction following rectal cancer surgery
Authors: Soon Yoon, Taek-Gu Lee, Joung Han, Hee Chae, Seon Park, Sei Youn, Sang-Jeon Lee
Journal: Endoscopy (2014)

Anastomotic stenosis is a well-recognized and troublesome complication following colorectal surgery. Conventionally, cases of complete obstruction have been treated conservatively with a permanent stoma, or have been managed by reoperation with its accompanying risks of morbidity [1] [2] [3] [4]. We report successful endoscopic treatment using a knife in a patient with complete anastomotic obstruction following rectal surgery.
Splenosis Detected by Heat-Denaturated Tc-99m Red Blood Cell Scintigraphy
Authors: LOUIS LAFLAMME, LUC BOUCHER
Journal: Clinical Nuclear Medicine (2003)

From the Department of Nuclear Medicine, Notre-Dame Hospital, Montreal, Canada Received for publication June 17, 2002. Revision accepted August 26, 2002. Correspondence: Louis Laflamme, Department of Nuclear Medicine, Notre-Dame Hospital, CHUM, 1560 Sherbrooke East, Montreal, Canada, H2L 4M1. E-mail: [email protected]
Are Mammograms a Good Idea for ATM Gene Carriers?
Authors: J. Randal
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Are Mammograms a Good Idea for ATM Gene Carriers? Get access Judith Randal Judith Randal Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 18, 20 September 1995, Page 1351, https://doi.org/10.1093/jnci/87.18.1351 Published: 20 September 1995
Individualized Stabilization Criteria–Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion
Authors: Ramin Tadayoni, Sebastian M. Waldstein, Francesco Boscia, Heinrich Gerding, Ian Pearce, Siegfried Priglinger, Andreas Wenzel, Elizabeth Barnes, Margarita Gekkieva, Stefan Pilz, Jordi Monés
Journal: Ophthalmology (2016)

To compare the 6-month efficacy and safety profile of an individualized stabilization criteria-driven pro re nata (PRN) regimen of ranibizumab 0.5 mg with or without laser versus laser alone in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO).A 24-month, prospective, open-label, randomized, active-controlled, multicenter, phase IIIb study.A total of 455 patients.Eligible patients were randomized 2:2:1 to receive ranibizumab (n = 183), ranibizumab with laser (n = 180), or laser only (n = 92). Patients treated with ranibizumab with or without laser received a minimum of 3 initial monthly ranibizumab injections until visual acuity (VA) stabilization, and VA-based PRN dosing thereafter. In the ranibizumab with laser and laser-only groups, laser was given at the investigator's discretion at a minimum interval of 4 months and if VA was <79 letters.Mean change from baseline at month 6 in best-corrected visual acuity (BCVA) (primary end point) and central subfield thickness, and safety over 6 months. Exploratory objectives were to evaluate the influence of baseline BCVA, disease duration, and ischemia on BCVA outcomes at month 6.Baseline mean BCVA was 57.7 letters, and mean BRVO duration was 9.9 months. Ranibizumab with or without laser was superior to laser only in improving mean BCVA from baseline at month 6 (14.8 and 14.8 vs. 6.0 letters; both P < 0.0001; primary end point met). Patients with a shorter BRVO duration at baseline had a higher mean BCVA gain than those with a longer BRVO duration. Patients with a poor baseline VA had a better BCVA gain than those with a higher baseline VA, although final BCVA was lower in those with poor baseline VA. In the ranibizumab with or without laser groups, the presence of some macular ischemia at baseline did not influence mean BCVA gains. There were no new ocular or nonocular safety events.Ranibizumab with an individualized VA-based regimen, with or without laser, showed statistically significant superior improvement in BCVA compared with laser alone in patients with BRVO. Overall, there were no new safety events other than those reported in previous studies.
<i>Taenia saginata</i> Infestation
Authors: Jian Li, Eping Guo
Journal: New England Journal of Medicine (2016)

A 38-year-old man presented with worsening abdominal pain, vomiting, anorexia, generalized weakness, and weight loss that had begun 3 days earlier. He had a history of eating raw beef. Examination of stool showed an embryonated egg containing an oncosphere.
Localization of a Parathyroid Adenoma by the Addition of Pinhole Imaging to Tc-99m Sestamibi Dual-Phase Scintigraphy
Authors: MICHAEL S. KIPPER, JUDITH J. LABARBERA, LINDA D. KROHN, LISA M. MARCOU
Journal: Clinical Nuclear Medicine (1997)

Scintigraphy using Tc-99m has been shown to be highly sensitive in localizing abnormal parathyroid glands in patients with hyperparathyroidism. False-negative studies most often are attributed to glandular size or location. The authors report a case of negative parathyroid imaging using standard dual-phase technique, which was converted to a positive study by the addition of a pinhole view. During a 1-year period, the authors systematically added an anterior-pinhole image of the neck to all equivocal or negative Tc-99m studies. Five of 19 patient studies were pinhole-image positive and standard-image negative or equivocal. In selected patients undergoing Tc-99m scintigraphy for hyperparathyroidism, the addition of a pinhole view may enhance study sensitivity and the confidence in interpretation.
MEPs back stronger controls on medical devices
Authors: R. Watson
Journal: BMJ (2014)

The European parliament has overwhelmingly approved stricter monitoring and certification procedures for medical devices such as breast or hip implants. The measures, which are designed to increase patient safety and to strengthen the traceability of medical products, were approved in Brussels on 2 April by 541 votes to 19, with 63 abstentions.

However, the draft legislation has a long way to travel before it reaches the statute book. European Union governments, whose approval is also required, are still examining the proposal that the European Commission tabled in September 2012 and are far from agreeing on …
P767Automated detection and measurement of isolated retinal arterioles by a combination of edge enhancement and cost analysis
Authors: JA Fernandez, P Bankhead, H Zhou, JG Mcgeown, TM Curtis
Journal: Cardiovascular Research (2014)

Purpose: Pressure myography studies have played a crucial role in our understanding of vascular physiology and pathophysiology. Such studies depend upon the reliable measurement of changes in the diameter of isolated vessel segments over time. Although several software packages are available to carry out such measurements on arteries and veins, no software exists to study smaller vessels (<50μm in diameter). The purpose of this study is to present a new algorithm to assist with the measurement and tracking of the diameters of small arterioles.
Abstract 4121: Leukemic FLT3 signals via Grb10 and elevated Grb10 expression correlates with poor prognosis in acute myeloid leukemia.
Authors: Kazi J. Uddin, Lars Rönnstrand
Journal: Cancer Research (2013)

Abstract The adaptor protein Grb10 plays important roles in mitogenic signaling. However, its roles in acute myeloid leukemia (AML) are predominantly unknown. Here we describe the role of Grb10 in FLT3-ITD-mediated AML. The type III receptor tyrosine kinase, FLT3 is widely expressed in AML and approximately 30% of AML patients carry an oncogenic FLT3-internal tandem duplication (ITD) mutation. We observed that Grb10 physically associates with normal and oncogenic FLT3 through FLT3 phospho-tyrosine 572 and 793 residues. Although Grb10 expression did not affect FLT3 activation or stability, its expression enhanced FLT3-mediated Akt and STAT5 phosphorylation without affecting Erk or p38 phosphorylation. Selective Grb10 depletion reduced Akt and STAT5 phosphorylation in Ba/F3 and OCI-AML-5 cells. Grb10 regulates cell cycle by accelerating G2-M transition followed by an increased cell population in S-phase. Expression of Grb10 furthermore resulted in an increased proliferation, survival and colony formation of Ba/F3-FLT3-ITD cells. Grb10 expression was significantly increased in AML patients compared to healthy controls and was also elevated in patients carrying FLT3-ITD mutants. The elevated Grb10 expression correlated to relapse as well as to poor prognosis. In addition, Grb10 expression led to resistance to chemotherapy. These results suggest that Grb10 binds to FLT3 and induces PI3K-Akt and STAT5 signaling pathways resulting in an enhanced proliferation, survival and colony formation of hematopoietic cells that furthermore initiates drug-resistance and poor prognosis in AML. Citation Format: Kazi J. Uddin, Lars Rönnstrand. Leukemic FLT3 signals via Grb10 and elevated Grb10 expression correlates with poor prognosis in acute myeloid leukemia. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4121. doi:10.1158/1538-7445.AM2013-4121
IMCT-22PHASE I STUDY OF FOURTH VENTRICLE INFUSIONS OF AUTOLOGOUS EX VIVO EXPANDED NK CELLS IN CHILDREN WITH RECURRENT/REFRACTORY POSTERIOR FOSSA TUMORS OF THE CENTRAL NERVOUS SYSTEM
Authors: Wafik Zaky, David Sandberg, Leena Ketonen, Laurence Cooper, Vidya Gopalakrishnan, Diane Liu, Judy Moyes, Dean Lee, Soumen Khatua
Journal: Neuro-Oncology (2015)

BACKGROUND: Over 300 children annually are affected in the USA with recurrent/refractory medulloblastoma, ependymoma and atypical teratoid/rhabdoid neoplasms (AT/RT) - the major malignant posterior fossa tumors (MPFT). The prognosis of these children remains dismal as most of them succumb to their disease. It is imperative to profile less toxic novel therapies to provide a meaningful cure. STUDY OBJECTIVES: 1) To establish the safety, feasibility, efficacy, and maximum tolerated dose (MTD) of administering autologous natural killer (NK) cells directly into the fourth ventricle in recurrent /refractory MPFT, 2) To preliminary assess the antitumor activity and 3) Correlative biologic studies: immunophenotype and function of expanded NK cells will be evaluated. ELIGIBILITY: Patient is  50, histologically confirmed recurrent medulloblastoma, ependymoma and AT/RT involving the brain and/or spine at original diagnosis or relapse will be eligible. Patient has either measurable or evaluable tumor, adequate CSF flow by MRI with CINE sequence, adequate bone marrow and liver function, life expectancy >12 weeks. EXPERIMENTAL DESIGN: Patients will receive 3 cycles of NK-cell infusions over 12 weeks through an ommaya reservoir connected to a catheter placed in the fourth ventricle. Each cycle consists of 3 NK-cell infusions per week for 3 weeks followed by a rest week. Response will be evaluated by MRI scans after the first and the third cycle and aspirated CSF prior to the NK cell infusions. Two to six evaluable patients per dose level (4 dose levels) will be entered in this study for determination of MTD. A minimum of 9 patients and a maximum of 24 patients will be enrolled.
FRI0562-HPR Effectiveness of the Introduction of Proprioceptive Training in the Exercise Programs for Knee Osteoarthritis
Authors: A.R.D. Carrasqueira, F.M. Pimentel-Santos, M. Gomes da Silva, J. Branco
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatic diseases are a major social and economic problem, with increasing negative impact on public health. The prevalence of Knee Osteoarthritis (KO) among older people is increasing and it seems to be associated with proprioceptive deficits. <h3>Objectives</h3> To investigate the effectiveness of the introduction of proprioceptive training in the current program guidelines-eight week duration (Arthritis Foundation, 2009), on range of motion, pain and stiffness of the knee, as well as in physical function and quality of life of clients with knee osteoarthritis. <h3>Methods</h3> A quasi-experimental study of eight weeks was implemented, with two independent samples of subjects with knee osteoarthritis (class II-II Kellgren-Lawrence scale) aged 50 and older. It is a controlled non randomized study, with a convenience sample of 42 subjects. Subjects in the experimental group (n=21) underwent the current exercise program guidelines (Arthritis Foundation, 2009) with the additional proprioceptive training, whilst the control group (n=21) attended the current exercise program guidelines (Arthritis Foundation, 2009). Both programes were defined according to the guidleines proposed by the Arthritis Foundation (2009) for this condition. Assessment was carried out at baseline and at the end of eight weeks, on the following outcomes: range of motion of the knee (goniometer), pain, stiffness and function and quality of life [Knee and Osteoarthritis Outcome Score (KOOS)]. <h3>Results</h3> The sample consisted of 42 caucasian subjects, mostly females (83.3%) with an average age of 72.1 years (SD=7.23). At the end of the progamme there was a statistically significant improvement of all outcomes in both groups. The introduction of proprioceptive training in the current program guidelines introduces a significantly higher evolution on the knee9s rom (extension - p&lt;0.05) on the sport/leisure function (p&lt;0.0001) and on the quality of life of participants (p&gt;0.050). <h3>Conclusions</h3> The results obtained suggest that exercise training introduces a positive effect on the most relevant symptoms, function and quality of life of subjects with knee osteoarthritis. The introduciton of of proprioceptive trainning appears to additionally improve some of the most relevant outcomes for patients with KO, according to the Arthritis Foundation, 2009: knee extension range of motion, sports and leasure and quality of life. For this reason we suggest that its introduction in the exercise plan should be considered. <h3>References</h3> Foundation, A. (2009). Arthritis Foundation Exercise Program. Instructor9s Manual. Atlanta: Arthritis Foundation. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5083
596 GENE PROFILING REVEALS ABNORMAL INDUCIBILITY OF INFLAMMATORY CYTOKINES AND DEFECTIVE ANTIGEN PROCESSING BY LYSOSOME MHC CLASS II COMPARTMENT IN LPS-STIMULATED IMMUNE CELLS FROM CIRRHOTIC PATIENTS
Authors: S. Gandoura, E. Weiss, P.-E. Rautou, M. Fasseu, F. Lemoine, C. Hego, D. Valla, D. Lebrec, P. De la Grange, R. Moreau
Journal: Journal of Hepatology (2012)
AB1043 Etanercept Retention Rates in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis
Authors: C.V. Dongen, E. Kneepkens, E. Vogelzang, M. l'Ami, C. Krieckaert, I. van der Horst, A. Voskuyl, M. Nurmohamed
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Anti-TNF therapy with etanercept is, according to clinical trials, effective in approximately 60 - 70% of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA). However, some patients experience adverse events or do not respond to therapy with these drugs leading to a shorter retention. <h3>Objectives</h3> To evaluate and compare retention rates of etanercept in patients with RA, AS or PsA treated with etanercept. <h3>Methods</h3> A total of 606 patients with RA, 230 patients with AS and 157 patients with PsA were consecutively included in observational cohorts. CRP, BSE (RA, AS, PSA), DAS28 (RA, PSA), BASFI and BASDAI (AS) were collected during follow-up. Data with respect to moment and reason of dropout were collected. <h3>Results</h3> Five year follow-up data was available for 350 patients with RA, 180 patients with AS and 108 patients with PsA. The proportion of patients with RA that was still on drug at five years (25%) was significantly (p&lt;0.05) lower than that of patients with AS (43%) and PSA (41%). Disease activity improved significantly (p&lt;0.05) compared to baseline, at six months and remained stable thereafter up to five years, in all three disease. <h3>Conclusions</h3> Disease activity in etanercept treated patients with RA, AS or PsA improved significantly at six months and stabilizes thereafter. The five year retention rate is the highest (&gt;40%) in patients with AS and PSA, whereas only 25% of patients with RA is still on drug five years after start of therapy. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5199
Albright's Hereditary Osteodystrophy
Authors: Arturo R. Rolla, Rene Rodriguez-Gutierrez
Journal: New England Journal of Medicine (2012)

A 71-year-old woman presented to the clinic for management of hypertension. On physical examination, she was found to have an absence of the fourth knuckle on each hand and brachymetatarsia of the fourth toes.
ONSET OF IN-HOSPITAL COMPLICATIONS IN ACUTE TYPE B AORTIC DISSECTIONS INITIALLY UNCOMPLICATED
Authors: Arnoud Kamman, Alan Braverman, Eduardo Bossone, Thomas Gleason, Toru Suzuki, Reed Pyeritz, Kevin Harris, Hans-Henning Eckstein, Udo Sechtem, Gilbert Upchurch, Kevin Greason, Daniel Montgomery, Eric Isselbacher, Christoph A. Nienaber, Kim Eagle, Santi Trimarchi
Journal: Journal of the American College of Cardiology (2016)
A10.15 LASP-1 modifies ECM-synovial fibroblast interactions in a mouse model of ra
Authors: D Beckmann, J Hillen, M Heitzmann, U Hansen, HP Kiener, CS Chew, S Butz, D Vestweber, H Pavenstädt, HJ Galla, T Pap, A Korb-Pap
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> The LIM-and-SH3-domain-protein-1 (Lasp-1) is an actin-associated protein and is localised at focal adhesion sites where it is involved in organisation of actin polymerization and focal adhesion turnover prozesses. We investigated its role in regulating synovial fibroblast (SF) interaction with components of the extracellular matrix (ECM) and in establishing cell-cell contacts during RA. <h3>Materials and methods</h3> Lasp-1 expression was analysed in tissue from RA patients and in the hind paws of arthritic hTNFtg mice by Western blot, immunofluorescence and immunohistochemistry. Furthermore, Lasp-1<sup>-/-</sup> mice were interbred with hTNFtg mice and offsprings were analysed for the progression of joint destruction by clinical evaluation and histopathology. Migration characteristics of SF derived from wild type (wt), Lasp-1<sup>-/-</sup>, hTNFtg and Lasp1<sup>-/-</sup>/hTNFtg mice were analysed in a modified scratch assay and by live cell imaging. Cell-matrix interactions and cell-cell contacts of isolated SF from all different genotypes were investigated using fibronectin coating in an electrical cell/substrate impedance sensing assay (ECIS). Additionally, we used an <i>in vitro </i>three-dimensional organ culture system for functional analyes. <h3>Results</h3> Lasp-1 expression levels were increased in human RA tissue and hTNFtg mice in comparison to healthy controls. Evaluation of Lasp-1<sup>-/-</sup>/hTNFtg mice revealed milder arthritis score compared to hTNFtg mice,which was confirmed by immunohistochemistry. Results of the scratch assays demonstrated a significantly reduced migration rate of Lasp-1<sup>-/-</sup> SF (-43,7% vs wt SF) and Lasp-1<sup>-/-</sup>/hTNFtg SF (-69,11% vs hTNFtg SF). Furthermore, live cell imaging studies demonstrated striking differences in the migration velocity and in migration edge formation of Lasp-1<sup>-/-</sup>/hTNFtg SF compared to hTNFtg SF. ECIS analysis demonstrated an increased cell-cell contact formation in Lasp1<sup>-/-</sup> compared to wt SF (+22% versus wt SF) and&nbsp;prolonged cell-cell interaction remodelling&nbsp;of Lasp-1<sup>-/-</sup>/hTNFtg SF in comparison to hTNFtg SF. Histological analysis of 3D matrices showed that Lasp-1 deletion in the hTNFtg background resulted in an organised cellular lining layer at the interface between the matrix and fluid phases comparable with wild type SF. In contrast, hTNFtg SF formed unorganised cellular condensations with no synovial architecture evident. <h3>Conclusion</h3> Lasp-1 regulates the migratory behaviour of synovial fibroblasts in rheumatoid arthritis by controlling the dynamics of cell-matrix and cell-cell contacts.